Marshall Islands vs Philippines: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Marshall Islands
0.9%
in 2024
Philippines
0.8%
in 2024
Marshall Islands rank
35th
Philippines rank
37th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Marshall Islands
- Philippines
How they compare
Marshall Islands currently reports 0.9% against 0.8% in Philippines, a difference of 0.1%.
That makes Marshall Islands's figure about 1.1 times Philippines's.
Across all 10 years both countries report, Marshall Islands has been ahead every year.
Marshall Islands ranks 35th and Philippines ranks 37th of 215 countries.
Marshall Islands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Marshall Islands | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.4% | 0.9% | 0.5% | Marshall Islands |
| 2020s | 1.0% | 0.9% | 0.2% | Marshall Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Marshall Islands or Philippines?
- Marshall Islands, at 0.9% against 0.8% in Philippines as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Marshall Islands and Philippines?
- 0.1%, with Marshall Islands ahead.
- How many years of comparable data are there for Marshall Islands and Philippines?
- 10 years are reported by both, from 2015 to 2024.
- How do Marshall Islands and Philippines rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Marshall Islands ranks 35th and Philippines ranks 37th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.